What You Need To Know Before Buying TYME Technologies Inc (NASDAQ: TYME) Stock

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

TYME Technologies is a new biotechnology company that develops “cancer metabolism-based therapies” or CMBTs. These treatments are designed to work across a wide range of diagnoses, solid tumors, hematologic cancers and more. The stock is trending higher after receiving patent notification for its metabolomic technology platform.

Step 1: Open up a brokerage account.

Open a brokerage account when you are ready to invest. Start with one of the brokers curated by Benzinga. These brokers are chosen due to their fair pricing, quality customer service and additional investment options. 

Step 2: Select your number of shares. 

The number of shares you buy depends primarily on your budget. You should consider your current position on TYME stock. Review the volatility of the market, the industry and the company. Plus, you need to know that you are buying at the most appropriate price for your portfolio.

Step 3: Choose an order type.

Your order type determines when and how you buy or sell TYME shares. 

Market orders buy and sell at the current price.

Limit orders buy or sell a price you set ahead of time.

Immediate or cancel orders must be completed immediately or they are canceled because the price of the stock could fluctuate wildly.

Step 4: Execute your trade.

Press the button and complete your trade. Check your online dashboard. Decide which stock you wish to buy next. Review your position, and visit Benzinga to research your next move.

TYME History

Try Benzinga Pro when you want to learn more about TYME stock or any other brand. As you can see, there is historical information, a range of indicators and real-time data for any trader.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.